Last $4.92 USD
Change Today +0.04 / 0.82%
Volume 1.6M
VVUS On Other Exchanges
As of 8:10 PM 07/9/14 All times are local (Market data is delayed by at least 15 minutes).

vivus inc (VVUS) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/12/13 - $15.40
52 Week Low
05/21/14 - $4.56
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for VIVUS INC (VVUS)

vivus inc (VVUS) Related Businessweek News

View More BusinessWeek News

vivus inc (VVUS) Details

VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health in the United States and the European Union. The company offers Qsymia, a drug for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also developing Qsymia, which has completed Phase II clinical studies for the treatment of obstructive sleep apnea and diabetes. The company has an agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. VIVUS, Inc. was founded in 1991 and is headquartered in Mountain View, California.

98 Employees
Last Reported Date: 02/28/14
Founded in 1991

vivus inc (VVUS) Top Compensated Officers

Chief Executive Officer, Chief Commercial Off...
Total Annual Compensation: $212.1K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $274.8K
Senior Vice President of Business Development...
Total Annual Compensation: $398.8K
Vice President of Clinical Development
Total Annual Compensation: $419.7K
Vice President of U S Operations and General ...
Total Annual Compensation: $369.9K
Compensation as of Fiscal Year 2013.

vivus inc (VVUS) Key Developments

VIVUS Inc. Announces Resignation of Robert N. Wilson, Board of Director

On June 10, 2014, Robert N. Wilson notified VIVUS Inc. of his decision to resign from the company's Board of Directors, or the Board, effective June 20, 2014. As previously reported, Mr. Wilson had informed the company that he was not standing for re-election to the Board at the next annual meeting of stockholders, which had been tentatively scheduled to be held on June 20, 2014. Mr. Wilson's decision to resign was not due to any disagreement with the company, including with respect to any matter relating to the company's operations, policies or practices.

VIVUS Inc. Presents at 2014 Wells Fargo Healthcare Conference, Jun-17-2014 08:15 AM

VIVUS Inc. Presents at 2014 Wells Fargo Healthcare Conference, Jun-17-2014 08:15 AM. Venue: InterContinental Hotel Boston, 510 Atlantic Avenu, Boston, MA 02210, United States. Speakers: Dana Shinbaum, Corp Development & IR, Seth H. Z. Fischer, Chief Executive Officer, Chief Commercial Officer and Director.

Aspen Mulls Offer For VIVUS

Aspen Investment Management Inc. (Aspen) expects to submit its non-binding offer to purchase VIVUS Inc. (NasdaqGS:VVUS) by June 13, 2014 in a deal valued at $640 million. The terms of the offer were not disclosed. In a regulatory filing, Aspen Investment Management said it planned to engage in discussions with Vivus regarding its board, management, operations and strategic plans, among other matters. While Vivus declined to comment on Aspen's planned offer, while Aspen was not immediately available for comment.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VVUS:US $4.92 USD +0.04

VVUS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arena Pharmaceuticals Inc $4.95 USD -0.06
GlaxoSmithKline Consumer Healthcare Ltd 4,722 INR +29.15
GlaxoSmithKline PLC 1,566 GBp +9.50
Roche Holding AG SFr.261.70 CHF -3.80
View Industry Companies

Industry Analysis


Industry Average

Valuation VVUS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.5x
Price/Book 3.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VIVUS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at